The success of anti-TNF therapy in treating patients with very active RA may therefore by explained, in part, by blockade of TNF-α-induced production of other mediators of inflammation, such as chemokines, by neutrophils and other immune cells. Here, TNF is linked to rheumatoid arthritis.